首页 | 本学科首页   官方微博 | 高级检索  
     

股腘段下肢动脉硬化闭塞症:载药腔内治疗的循证医学证据
引用本文:张锐,来志超,刘昌伟. 股腘段下肢动脉硬化闭塞症:载药腔内治疗的循证医学证据[J]. 中国医学科学院学报, 2019, 41(2): 256-260. DOI: 10.3881/j.issn.1000-503X.10849
作者姓名:张锐  来志超  刘昌伟
作者单位:中国医学科学院 北京协和医学院 北京协和医院血管外科,北京 100730
摘    要:
随着生活水平的提高以及老龄化的加剧,动脉粥样硬化相关疾病的危害日益凸显。目前,全球约有2亿人因下肢动脉硬化闭塞症(ASO)的困扰而影响了正常的生活,甚至威胁生命。从上世纪40年代至今的短短70余年里,ASO手术治疗及腔内治疗经历快速发展,其中腔内治疗的方式也逐渐从单纯球囊扩张及金属裸支架置入发展到药物涂层球囊、药物洗脱支架等一系列新技术上,但目前新技术、新器材在ASO股腘段病变的实际临床效果、适应证等仍在探索之中。本文就现有的ASO股腘段病变载药腔内治疗手段的相关循证医学证据进行阐述。

关 键 词:下肢动脉硬化闭塞症  股腘段病变  药物涂层球囊  药物洗脱支架  
收稿时间:2018-09-14

Femoral-popliteal Arteriosclerosis Obliterans:Review of Evidence-based Studies on Drug-eluting Endovascular Treatment
ZHANG Rui,LAI Zhichao,LIU Changwei. Femoral-popliteal Arteriosclerosis Obliterans:Review of Evidence-based Studies on Drug-eluting Endovascular Treatment[J]. Acta Academiae Medicinae Sinicae, 2019, 41(2): 256-260. DOI: 10.3881/j.issn.1000-503X.10849
Authors:ZHANG Rui  LAI Zhichao  LIU Changwei
Affiliation:Department of Vascular Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China
Abstract:
Atherosclerosis-related diseases have increasingly become health concerns with the increased living conditions and aging.Globally,about 200 million people have suffered from arteriosclerosis obliterans(ASO),which can even be life-threatening in some cases.The past seven decades have witnessed the rapid advances in the treatment of ASO,which has developed from surgery to endovascular interventions including plain balloon angioplasty,bare metal stent placement,drug-coated balloon,and drug-eluting stent.However,the roles of these new techniques for femoral-popliteal lesions,especially their real-world clinical outcomes and indications,remain unclear.This article reviews the latest evidences on the use of drug-eluting devices in treating femoral-popliteal arteriosclerosis obliterans.
Keywords:arteriosclerosis obliterans  femoral-popliteal lesion  drug-coated balloon  drug-eluting stent  
点击此处可从《中国医学科学院学报》浏览原始摘要信息
点击此处可从《中国医学科学院学报》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号